Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM1 | Q13255 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.41 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | GFER | P55789 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | CASP3 | P42574 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31571092 | 0.86 | KMT2A (0.50) | GRM1CYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL379382 | 0.86 | KMT2A (0.50) | GRM1CYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL1767828 | 0.84 | KMT2A (0.61) | GRM1CYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL1767710 | 0.83 | ALDH1A1 (0.49) | GRM1CYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL25587992 | 0.82 | GRM1 (0.48) | GRM1RXFP1KMT2APSMB5MAPT | |
| SCHEMBL8354251 | 0.81 | GRM1 (0.50) | GRM1CYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL12000236 | 0.81 | MAPT (0.58) | GRM1CYP1A2RXFP1KMT2AMAPT | |
| SCHEMBL23151910 | 0.79 | GRM1 (0.42) | GRM1RXFP1MAPTHTTALDH1A1 | |
| SCHEMBL8353989 | 0.79 | KMT2A (0.42) | GRM1CYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL12345561 | 0.79 | MAPT (0.47) | CYP1A2CYP2D6CYP2C9CYP2C19RXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1687277-B1 | 6-ALKENYL AND 6-PHENYLALKYL SUBSTITUTED 2-QUINOLINONES AND 2-QUINOXALINONES AS POLY(ADP-RIBOSE) POLYMERASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-04-04 | — | — | EP | disclosed |
| US-9115084-B2 | 6-alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(ADP-ribose) polymerase inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2015-08-25 | — | — | US | disclosed |
| US-8802671-B2 | Quinoline derivatives as antibacterial agents | JANSSEN PHARMACEUTICA NV (BE) | 2014-08-12 | — | — | US | disclosed |
| US-20130237528-A1 | 6-ALKENYL AND 6-PHENYLALKYL SUBSTITUTED 2-QUINOLINONES AND 2-QUINOXALINONES AS POLY(ADP-RIBOSE) POLYMERASE INHIBITORS | JANSSEN PHARMACEUTICA, NV (BE) | 2013-09-12 | — | — | US | disclosed |
| US-8450486-B2 | 6-alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(ADP-ribose) polymerase inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2013-05-28 | — | — | US | disclosed |
| EP-1912648-B1 | QUINOLINE DERIVATIVES AS ANTIBACTERIAL AGENTS | JANSSEN PHARMACEUTICA NV (BE) | 2013-04-10 | — | — | EP | disclosed |
| US-20120046274-A1 | 6-ALKENYL AND 6-PHENYLALKYL SUBSTITUTED 2-QUINOLINONES AND 2-QUINOXALINONES AS POLY(ADP-RIBOSE) POLYMERASE INHIBITORS | MABIRE DOMINIQUE JEAN-PIERRE (FR) | 2012-02-23 | — | — | US | disclosed |
| US-8071612-B2 | 6-alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(ADP-ribose) polymerase inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2011-12-06 | — | — | US | disclosed |
| CN-1910154-B | Quinoline derivatives as mycobacterial inhibitors | JANSSEN PHARMACEUTICA NV | 2011-08-17 | — | — | CN | disclosed |
| US-20110160208-A1 | DIARYL-SUBSTITUTED FIVE-MEMBERED HETEROCYCLE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2011-06-30 | — | — | US | disclosed |
| US-20070072842-A1 | 6-Alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(adpribose) polymerase inhibitors | JANSSEN-CILAG (FR) | 2007-03-29 | — | — | US | disclosed |
| CN-1934094-A | Diaryl substituted heterocyclic 5-membered ring derivatives | BANYU PHARMA CO LTD (JP) | 2007-03-21 | — | — | CN | disclosed |
| WO-2007014941-A2 | QUINOLINE DERIVATIVES AS ANTIBACTERIAL AGENTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-02-08 | — | — | WO | disclosed |
| CN-1910154-A | Quinoline derivatives as mycobacterial inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2007-02-07 | — | — | CN | disclosed |
| CN-1882547-A | 6-alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(adp-ribose) polymerase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2006-12-20 | — | — | CN | disclosed |
| EP-1713776-A1 | QUINOLINE DERIVATIVES FOR USE AS MYCOBACTERIAL INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-10-25 | — | — | EP | disclosed |
| EP-1687277-A1 | 6-ALKENYL AND 6-PHENYLALKYL SUBSTITUTED 2-QUINOLINONES AND 2-QUINOXALINONES AS POLY(ADP-RIBOSE) POLYMERASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-08-09 | — | — | EP | disclosed |
| WO-2005075428-A1 | QUINOLINE DERIVATIVES FOR USE AS MYCOBACTERIAL INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-08-18 | — | — | WO | disclosed |
| WO-2005054201-A1 | 6-ALKENYL AND 6-PHENYLALKYL SUBSTITUTED 2-QUINOLINONES AND 2-QUINOXALINONES AS POLY(ADP-RIBOSE) POLYMERASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-06-16 | — | — | WO | disclosed |
| WO-2003082350-A2 | RADIOLABELLED QUINOLINE AND QUINOLINONE DERIVATIVES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR LIGANDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072842-A1 | 6-Alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(adpribose) polymerase inhibitors | PARP1, PARP6, PARP2 | GRM1 3930/4885CYP1A2 665/4885CYP2D6 197/4885 |
| US-20110160208-A1 | DIARYL-SUBSTITUTED FIVE-MEMBERED HETEROCYCLE DERIVATIVE | OPRK1, GRM1, GRIK1 | GRM1 2/4885CYP1A2 975/4885CYP2D6 672/4885 |
| US-20130237528-A1 | 6-ALKENYL AND 6-PHENYLALKYL SUBSTITUTED 2-QUINOLINONES AND 2-QUINOXALINONES AS POLY(ADP-RIBOSE) POLYMERASE INHIBITORS | PARP1, PARP2, PARP6 | GRM1 4270/4885CYP1A2 587/4885CYP2D6 142/4885 |
| US-20120046274-A1 | 6-ALKENYL AND 6-PHENYLALKYL SUBSTITUTED 2-QUINOLINONES AND 2-QUINOXALINONES AS POLY(ADP-RIBOSE) POLYMERASE INHIBITORS | PARP1, PARP2, PARP6 | GRM1 4270/4885CYP1A2 587/4885CYP2D6 142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.